Citation Impact
Citing Papers
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
An engineered 4-1BBL fusion protein with “activity on demand”
2020
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2017
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2021
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
2020
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
2018 StandoutNobel
Expansive discovery of chemically diverse structured macrocyclic oligoamides
2024 StandoutScienceNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Control of Regulatory T Cells by Co-signal Molecules
2019 StandoutNobel
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Combination cancer immunotherapy and new immunomodulatory targets
2015
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
2010 Standout
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
2019
Delivery technologies for cancer immunotherapy
2019 Standout
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
2019 Standout
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
2014
Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
2017
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
2015
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Development of a safety and efficacy nanoemulsion delivery system encapsulated gambogic acid for acute myeloid leukemia in vitro and in vivo
2018
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Advances in Hypoxia-Inducible Factor Biology
2017
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Cyanine based Nanoprobes for Cancer Theranostics
2017
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
2018
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
2017
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
2021
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Development of Small-Molecule Cyclin D1-Ablative Agents
2006
Works of Bing Chen being referenced
Activity of Anti-PD-1 in Murine Tumor Models: Role of “Host” PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4 (48.37)
2007
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo
2016
Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma
2017
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
2016
Antisense to cyclin D1 reverses the transformed phenotype of human gastric cancer cells
1999
STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways
2016